Topic
Asco
Recent coverage of Asco from across the web.
-
STAT+: A standing ovation for RevMed, and caution for Akeso -
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug -
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA -
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer